Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Continuous drug delivery aiming continuous dopaminergic stimulation in Parkinson's disease

Van Wamelen, Daniel J. ; Grigoriou, Sotirios LU orcid ; Chaudhuri, K. Ray and Odin, Per LU orcid (2018) In Journal of Parkinson's Disease 8(s1). p.65-72
Abstract

Continuous dopaminergic stimulation in Parkinson's disease (PD) has several advantages over pulsatile, noncontinuous, stimulation. These therapies currently consist of pump-based and transcutaneous therapies and are based on a more constant delivery of the dopaminergic drug resulting in continuous dopaminergic stimulation and a more stable treatment effect. Several clinical and experimental observations have shown that continuous stimulation of dopaminergic receptors induces fewer complications, such as dyskinesia, compared to pulsatile stimulation. Currently available nonoral pharmacological continuous therapies in PD include the transdermal Rotigotine (RTG) patch, infusion therapies with Apomorphine and Intrajejunal Levodopa (IJLI)... (More)

Continuous dopaminergic stimulation in Parkinson's disease (PD) has several advantages over pulsatile, noncontinuous, stimulation. These therapies currently consist of pump-based and transcutaneous therapies and are based on a more constant delivery of the dopaminergic drug resulting in continuous dopaminergic stimulation and a more stable treatment effect. Several clinical and experimental observations have shown that continuous stimulation of dopaminergic receptors induces fewer complications, such as dyskinesia, compared to pulsatile stimulation. Currently available nonoral pharmacological continuous therapies in PD include the transdermal Rotigotine (RTG) patch, infusion therapies with Apomorphine and Intrajejunal Levodopa (IJLI) and the Rivastigmine patch. Here we aim to provide a concise review of these current therapies and discuss ongoing and future developments of continuous non-oral pharmacological dopaminergic therapies in PD.

(Less)
Please use this url to cite or link to this publication:
author
; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Apomorphine, Infusion pumps, Parkinson's disease, Rivastigmine, Rotigotine
in
Journal of Parkinson's Disease
volume
8
issue
s1
pages
65 - 72
publisher
IOS Press
external identifiers
  • pmid:30584160
  • scopus:85058850953
ISSN
1877-7171
DOI
10.3233/JPD-181476
language
English
LU publication?
yes
id
0d0bdaa1-6997-44a1-bcde-32e31913e027
date added to LUP
2019-01-11 09:14:07
date last changed
2024-03-18 22:49:59
@article{0d0bdaa1-6997-44a1-bcde-32e31913e027,
  abstract     = {{<p>Continuous dopaminergic stimulation in Parkinson's disease (PD) has several advantages over pulsatile, noncontinuous, stimulation. These therapies currently consist of pump-based and transcutaneous therapies and are based on a more constant delivery of the dopaminergic drug resulting in continuous dopaminergic stimulation and a more stable treatment effect. Several clinical and experimental observations have shown that continuous stimulation of dopaminergic receptors induces fewer complications, such as dyskinesia, compared to pulsatile stimulation. Currently available nonoral pharmacological continuous therapies in PD include the transdermal Rotigotine (RTG) patch, infusion therapies with Apomorphine and Intrajejunal Levodopa (IJLI) and the Rivastigmine patch. Here we aim to provide a concise review of these current therapies and discuss ongoing and future developments of continuous non-oral pharmacological dopaminergic therapies in PD.</p>}},
  author       = {{Van Wamelen, Daniel J. and Grigoriou, Sotirios and Chaudhuri, K. Ray and Odin, Per}},
  issn         = {{1877-7171}},
  keywords     = {{Apomorphine; Infusion pumps; Parkinson's disease; Rivastigmine; Rotigotine}},
  language     = {{eng}},
  number       = {{s1}},
  pages        = {{65--72}},
  publisher    = {{IOS Press}},
  series       = {{Journal of Parkinson's Disease}},
  title        = {{Continuous drug delivery aiming continuous dopaminergic stimulation in Parkinson's disease}},
  url          = {{http://dx.doi.org/10.3233/JPD-181476}},
  doi          = {{10.3233/JPD-181476}},
  volume       = {{8}},
  year         = {{2018}},
}